Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: CASEY  LONG
Organization: DYNPORT VACCINE COMPANY, LLC
Fiscal Year: 2024
Award: $245,549
Funding agency: National Institute of Allergy and Infectious Diseases

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases and can carry out all aspects of interventional clinical trial implementation.

Terms: <COVID-19 therapeutics><Clinical Trials><Clinical Trials Unit><Communicable Diseases><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Early-Stage Clinical Trials><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Intervention><Intervention Strategies><Investigation><NIAID><National Institute of Allergy and Infectious Disease><New Agents><Phase 1 Clinical Trials><Phase I Clinical Trials><Phase I Study><Placebo Control><Prevention><Randomized><SARS-CoV-2 therapeutics><SARS-coronavirus-2 therapeutics><Severe acute respiratory syndrome coronavirus 2 therapeutics><Study Subject><clinical trial implementation><coronavirus disease 2019 therapeutics><early clinical trial><early phase clinical trial><implementation of clinical trials><interventional strategy><phase 1 study><phase I protocol><placebo controlled><randomisation><randomization><randomly assigned><therapeutics against COVID-19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus>